FierceBiotech ٢٢ ديسمبر ٢٠٢٥ BioMarin quietly discards liver disease candidate after $4.8B Amicus announcement
FierceBiotech ٢٢ ديسمبر ٢٠٢٥ Boehringer spells out a $448M future for Rectify's ABC kidney disease program
FierceBiotech ٢٢ ديسمبر ٢٠٢٥ Editor's corner: Fierce Medtech's top 10 stories of 2025 show how tech can treat
FierceBiotech ٢٢ ديسمبر ٢٠٢٥ AstraZeneca fronts $100M for Jacobio's clinical-stage pan-KRAS inhibitor
FierceBiotech ٢٢ ديسمبر ٢٠٢٥ AstraZeneca flunks phase 3 lung cancer test in further setback to synthetic lethal mechanism
FierceBiotech ٢٠ ديسمبر ٢٠٢٥ Looking ahead with BD’s Bilal Muhsin on what good AI can still do for healthcare
FierceBiotech ٢٠ ديسمبر ٢٠٢٥ Ipsen's hopes for next-gen rare disease drug dashed by pivotal phase 2 fail
FierceBiotech ١٩ ديسمبر ٢٠٢٥ Merck turns down option to Evaxion's gonorrhea vaccine, prompting Danish biotech to seek other partners
FierceBiotech ١٩ ديسمبر ٢٠٢٥ Galapagos ends turbulent year with mixed results for last remaining immunology asset